Research programme: paracrine gene therapy - Renova

Drug Profile

Research programme: paracrine gene therapy - Renova

Alternative Names: AAV8.UCn2; Adeno-associated virus 8 vector encoding urocortin 2 - Renova Therapeutics; RT-110; RT-200; RT-210; RT-220; RT-230; RT-300; Urocortin-2 gene therapy - Renova

Latest Information Update: 28 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of California, San Diego
  • Developer Renova Therapeutics
  • Class Antihyperglycaemics; Cardiovascular therapies; Gene therapies; Hepatoprotectants; Obesity therapies
  • Mechanism of Action Adenylate cyclase stimulants; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Heart failure; Non-alcoholic fatty liver disease; Obesity; Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 24 Jun 2018 Preclinical trials in Type-1 diabetes mellitus in USA (IV) before June 2018
  • 24 Jun 2018 Pharmacodynamics data from a preclinical studies in Type 1 diabetes mellitus released by Renova Therapeutics
  • 04 May 2018 Pharmacodynamics data from a preclinical trial in Heart failure released by Renova Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top